These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28733266)

  • 1. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
    Mei MG; Cao TM; Chen L; Song JY; Siddiqi T; Cai JL; Farol LT; Al Malki MM; Salhotra A; Aldoss I; Palmer J; Herrera AF; Zain J; Popplewell LL; Chen RW; Rosen ST; Forman SJ; Kwak L; Nademanee AP; Budde LE
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1861-1869. PubMed ID: 28733266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.
    Graf SA; Stevenson PA; Holmberg LA; Till BG; Press OW; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Pagel JM; Maloney DG; Zhou Y; Cassaday RD; Gopal AK
    Ann Oncol; 2015 Nov; 26(11):2323-8. PubMed ID: 26347113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
    Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
    Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
    Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
    J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?
    Kumar A
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):155-162. PubMed ID: 36485104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
    Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang MI; Cohen JB; Calzada O; Churnetski MC; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast MA; Fenske TS; Narayana Rao Gari S; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns TF; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
    J Clin Oncol; 2019 Feb; 37(6):471-480. PubMed ID: 30615550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
    Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
    Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
    Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
    Romancik JT; Chen Z; Allen PB; Waller EK; Valla K; Colbert A; Rosand C; Palmer AF; Flowers CR; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1084-e1091. PubMed ID: 36180329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
    Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
    Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis.
    Hilal T; Wang Z; Almader-Douglas D; Rosenthal A; Reeder CB; Jain T
    Am J Hematol; 2018 Oct; 93(10):1220-1226. PubMed ID: 30033656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
    Martin P; Cohen JB; Wang M; Kumar A; Hill B; Villa D; Switchenko JM; Kahl B; Maddocks K; Grover NS; Qi K; Parisi L; Daly K; Zhu A; Salles G
    J Clin Oncol; 2023 Jan; 41(3):541-554. PubMed ID: 35763708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.